UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Babylon Holdings Limited
(Name of Issuer)

Class A ordinary shares, par value \$0.001056433113

(Title of Class of Securities)

G07031100 (CUSIP Number)

Anders F. Börjesson
c/o VNV (Cyprus) Limited
1, Lampousas Street, 1095 Nicosia, Cyprus
+46 8 545 015 50
(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

June 20, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. \Box

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

CUSIP NO. G07031100

CUSIP NO. 00/03	1100						
1	NAMES OF REPORTING PERSONS						
1	VNV (CYPRUS) LIMITED						
•	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
2	(a) □ (b) ⊠						
3	SEC USE ONLY						
3							
4	SOURCE OF FUNDS						
4	OO	00					
5	CHECK	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) \Box					
3	Not Appl	Not Applicable					
6	CITIZEN	CITIZENSHIP OR PLACE OF ORGANIZATION					
U	Cyprus	Cyprus					
		7	SOLE VOTING POWER				
		,	0				
NUMBER OF S	EACH ERSON 9	Q	SHARED VOTING POWER				
BENEFICIA OWNED BY F		0	2,461,232(1)				
REPORTING P.		0	SOLE DISPOSITIVE POWER				
WIIII			0				
		10	SHARED DISPOSITIVE POWER				
			2,461,232(1)				
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	2,461,232 ⁽¹⁾						
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
12							
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
	9.6%(2)						
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
14	co						

⁽¹⁾ Reflects (i) 2,363,467 Class A ordinary shares par value \$0.001056433113 (the "Class A Shares") of the Issuer held by VNV (Cyprus) Limited ("VNV Cyprus"), a wholly-owned subsidiary of VNV Global AB (publ) ("VNV Global"), a Swedish publicly traded company and (ii) 97,765 Class A ordinary shares held by Global Health Equity (Cyprus) Ltd ("Global Health Equity"). Global Health Equity is the holder of 709,812 Class A Shares. VNV Global indirectly holds, through its direct wholly-owned subsidiaries, VNV Sweden AB ("VNV Sweden") and VNV Cyprus, approximately 51.13% of the shares in Global Health Equity AB (publ) ("Global Health (publ)"), with the remainder held by other foreign institutional investors and individuals. VNV Global is the sole shareholder of VNV Sweden and VNV Cyprus. Investment decisions relating to holdings of VNV Sweden and VNV Cyprus are made by a board of directors consisting of thred individuals and four individuals, respectively, on the basis of recommendations issued by the six-member board of directors of VNV Global. Investment decisions relating to holdings of Global Health Equity are taken by a board of directors that consists of P.C. Nordic Administration Limited, taking into account recommendations issued by a three-member board of directors of Global Health (publ). The Global Health (publ) board is currently comprised of three members, constituting managing members of VNV Global.

⁽²⁾ The percentage calculated is based on 25,614,074 Class A Shares outstanding as of May 1, 2023 as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

CUSIP NO. G0703	1100							
1	NAMES OF REPORTING PERSONS							
1	GLOBAL HEALTH EQUITY (CYPRUS) LTD							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
2	(a) [(b)	$\text{(a)} \ \Box \ \text{(b)} \ \boxtimes$						
3	SEC USE ONLY							
3								
4	SOURCE	SOURCE OF FUNDS						
4	OO	00						
5	CHECK	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) □						
<u> </u>	Not Appl	Not Applicable						
6	CITIZENSHIP OR PLACE OF ORGANIZATION							
<u> </u>	Cyprus							
		7	SOLE VOTING POWER					
			0					
NUMBER OF S	LLY EACH	8	SHARED VOTING POWER					
BENEFICIAL OWNED BY E		0	709,812(1)					
REPORTING P		9	SOLE DISPOSITIVE POWER					
***************************************			0					
		10	SHARED DISPOSITIVE POWER					
			709,812 ⁽¹⁾					
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
	709,812 ⁽¹⁾							
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES							
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)							
	2.8%(2)							
1.1	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)							
14	со							

⁽¹⁾ Global Health Equity is the holder of 709,812 Class A Shares. VNV Global indirectly holds, through its direct wholly-owned subsidiaries, VNV Sweden and VNV Cyprus, approximately 51.13% of the shares in Global Health Equity (publ), with the remainder held by other foreign institutional investors and individuals. VNV Global is the sole shareholder of VNV Sweden and VNV Cyprus. Investment decisions relating to holdings of VNV Sweden and VNV Cyprus are made by a board of directors consisting of three individuals and four individuals, respectively, on the basis of recommendations issued by the six-member board of directors of VNV Global. Investment decisions relating to holdings of Global Health Equity are taken by a board of directors that consists of P.C. Nordic Administration Limited, taking into account recommedations issued by a three-member board of directors of Global Health (publ). The Global Health (publ) board is currently comprised of three members, constituting managing members of VNV Global.

⁽²⁾ The percentage calculated is based on 25,614,074 Class A Shares outstanding as of May 1, 2023 as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

CUSIP NO. G0703	31100						
1	NAMES OF REPORTING PERSONS						
1	VNV SWEDEN AB						
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
2	(a) □ (b) ⊠						
	SEC USE ONLY						
3							
	SOURCE OF FUNDS						
4	00						
_	CHECK I	BOX IF I	DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) \Box				
5	Not Appli	Not Applicable					
	CITIZEN	CITIZENSHIP OR PLACE OF ORGANIZATION					
6	Sweden	Sweden					
		7	SOLE VOTING POWER				
		7	0				
		0	SHARED VOTING POWER				
NUMBER OF S BENEFICIA	LLY	8	709,812(1)				
OWNED BY I		•	SOLE DISPOSITIVE POWER				
WITH		9	0				
		10	SHARED DISPOSITIVE POWER				
		10	265,130 ⁽¹⁾				
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	709,812 ⁽¹⁾						
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
12							
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
13	$2.8\%^{(2)}$						
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
14	СО						

⁽¹⁾ Global Health Equity is the holder of 709,812 Class A Shares. VNV Global indirectly holds, through its direct wholly-owned subsidiaries, VNV Sweden and VNV Cyprus, approximately 51.13% of the shares in Global Health Equity (publ), with the remainder held by other foreign institutional investors and individuals. VNV Global is the sole shareholder of VNV Sweden and VNV Cyprus. Investment decisions relating to holdings of VNV Sweden and VNV Cyprus are made by a board of directors consisting of three individuals and four individuals, respectively, on the basis of recommendations issued by the six-member board of directors of VNV Global. Investment decisions relating to holdings of Global Health Equity are taken by a board of directors that consists of P.C. Nordic Administration Limited, taking into account recommedations issued by a three-member board of directors of Global Health (publ). The Global Health (publ) board is currently comprised of three members, constituting managing members of VNV Global.

⁽²⁾ The percentage calculated is based on 25,614,074 Class A Shares outstanding as of May 1, 2023 as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

CUSID NO. CO7021100

CUSIP NO. G0703	31100							
	NAMES OF REPORTING PERSONS							
1	VNV Global AB (publ)							
_	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
2	(a) □ (b) ⊠							
3	SEC USE ONLY							
	SOURCE	SOURCE OF FUNDS						
4	00							
	CHECK	BOX IF I	DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) \Box					
5	Not Applicable							
_	CITIZEN	CITIZENSHIP OR PLACE OF ORGANIZATION						
6	Sweden							
		7	SOLE VOTING POWER					
		,	0					
			SHARED VOTING POWER					
NUMBER OF S BENEFICIA OWNED BY	LLY	8	3,073,279(1)					
REPORTING P	PERSON	•	SOLE DISPOSITIVE POWER					
WITH		9	0					
	10		SHARED DISPOSITIVE POWER					
		10	2,726,362 ⁽²⁾					
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
11	3,073,279(1)							
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
12								
4.5	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)							
13	12.0%(3)							
	TYPE OF REPORTING PERSON							
14	со							

⁽¹⁾ Reflects (i) 2,363,467 Class A Shares held by VNV Cyprus and (ii) 709,812 Class A Shares held by Global Health Equity.
(2) Reflects (i) 2,461,232 Class A Shares held by VNV Cyprus and (ii) 265,130 Class A Shares held by Global Health Equity.
(3) The percentage calculated is based on 25,614,074 Class A Shares outstanding as of May 1, 2023 as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

EXPLANATORY NOTE

This Amendment No. 1 amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the "SEC") on November 10, 2022 (as amended to date, the "Schedule 13D") with respect to the Class A Shares of Babylon Holdings Ltd. (the "Issuer"). Capitalized terms used herein and not otherwise defined shall have the same meanings ascribed to them in the Schedule 13D.

Item 1. Security and Issuer

This Amendment No. 1 to Schedule 13D (this "Amendment") relates to the Class A Shares of the Issuer, whose principal executive offices are located at 1 Knightsbridge Green, London, SW1X 7QA, United Kingdom.

Item 4. Purpose of Transaction

Between June 15, 2023 and June 28, 2023, VNV Cyprus sold 863,592 shares of Class A Shares of \$520,942.61 in the aggregate in open market sales. The shares were sold at prices ranging from \$0.56 to \$0.67.

Item 5. Interest in Securities of the Issuer

(a) – (b) Based on 25,614,074 Class A Shares outstanding as of May 1, 2023 as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

Reporting Person	Amount	Percent	Sole	Shared	Sole power	Shared
	beneficially	of class	power to	power to	to dispose	power to
	owned		vote or to	vote or to	or to direct	dispose or to
			direct the	direct the	the	direct the
			vote	vote	disposition	disposition
VNV Cyprus	2,461,232	9.6%	0	2,461,232	0	2,461,232
VNV Global	3,073,279	12.0%	0	3,073,279	0	2,726,362
Global Health Equity	709,812	2.8%	0	709,812	0	709,812
VNV Sweden	709,812	2.8%	0	709,812	0	265,130

Except as set forth above, neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the persons named in Schedule I hereto, beneficially own any Class A Shares.

(c) During the last 60 days, VNV Cyprus⁽¹⁾ effected the following transactions in the Issuer's Class A Shares:

Date	Amount	Price Per Share ⁽²⁾	Type of Transaction
June 15, 2023	93,228	\$0.58	Open market sale
June 16, 2023	46,275	\$0.58	Open market sale
June 20, 2023	131,038	\$0.57	Open market sale
June 21, 2023	58,183	\$0.56	Open market sale
June 22, 2023	62,457	\$0.58	Open market sale
June 23, 2023	186,111	\$0.62	Open market sale
June 26, 2023	141,547	\$0.67	Open market sale
June 27, 2023	41,328	\$0.64	Open market sale
June 28, 2023	103,425	\$0.57	Open market sale

⁽¹⁾ VNV Cyprus is a wholly-owned subsidiary of VNV Global, and VNV Global has the shared power to vote or to direct the vote and to dispose or direct the disposition of the Class A Shares held by VNV Cyprus.

(d) – (e) Not applicable.

⁽²⁾ The price per share does not reflect brokerage commissions paid.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 29, 2023

VNV (CYPRUS) LIMITED

By: /s/ Boris Sinegubko Name: Boris Sinegubko Title: Managing Director

GLOBAL HEALTH EQUITY (CYPRUS) LTD

By: P.C. Nordic Administration Limited

By: /s/ Maria Zembyla Name: Maria Zembyla, on behalf of P.C. Nordic

Administration Limited

Title: Director

VNV SWEDEN AB

By: /s/ Per Brilioth Name: Per Brilioth Title: Managing Director

VNV GLOBAL AB (PUBL)

By: /s/ Per Brilioth Name: Per Brilioth Title: Managing Director